In clinical practice, BC stratification is performed by the immunohistochemical determination of routine pathologic markers such as estrogen receptor α (ERα), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2), and by semiquantitative evaluation of Ki-67. Here, ERBB2 is linked to breast cancer.